You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
A biochemical companion diagnostic platform to measure kinase inhibitor pharmacodynamics in leukemiaSBC: MICROFLUIDIC INNOVATIONS, LLC Topic: 102
DESCRIPTION provided by applicant Kinase inhibitors created a new paradigm in chemotherapy and are a major focus of new oncology drug development The Bcr Abl inhibitor imatinib was a breakthrough drug for chronic myelogenous leukemia with overwhelming early results however at least of patients are either intolerant resistant or experience recurrence within years and individual respo ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
A Clinical 3D Movement Analysis System for Assessing Lower Extremity Injury Risk and Recovery in AthletesSBC: BIONIKS Topic: NIAMS
DESCRIPTION provided by applicant The mission of Bioniks is to develop and commercialize accurate low cost movement analysis systems for clinicians ergonomists athletic trainers and other professionals interested in quantifying human movement Our initial focus is on developing computer enhancements for inexpensive D cameras like the Microsoft Kinect These enhancements surpass the accura ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. Topic: NINDS
Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: MS Technologies Corporation Topic: NIA
DESCRIPTION provided by applicant Falls are a leading cause of injuries and deaths among older adults OAs and will be an increasing public health concern given projections of future increases in the number of OAs in the US Fall detection and or surveillance systems are needed to enhance an OAandapos s confidence and independence and to facilitate rapid post fall responses This project wil ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: SEACOAST SCIENCE, INC. Topic: NIEHS
Project Summary This Small Business Technology Transfer Phase I project proposes the development and optimization of a commercially viable novel polymer based radiation dosimeter for wide spread deployment The radiation dosimeter proposed herein is a disruptive technology with a significant market Although many commercial radiation dosimeters measure individual radiation load dose quantificatio ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Brain Solutions, LLC Topic: NIDA
TBDSTTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: IMMvention Therapeutix, Inc. Topic: NIAID
Summary Influenza virusa member of the orthomyxovirus familyhas three different types that infect humansABand CTypes A and B produce annual epidemicsand type A influenzawhich resides asymptomatically in birdscan cause pandemic infections in humansIn addition to common flu like symptomse gfeverchillsmalaisemuscle painin susceptible populations influenza can induce potentially fatal secondary compli ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Anasys Instruments Corp. Topic: 300
DESCRIPTION provided by applicant Anasys Instruments and Prof Lynne Taylor of Purdue propose to develop nanoscale chemical characterization capabilities for drug formulation research This project will build on successful Phase I research demonstrating feasibility of atomic force microscope based infrared spectroscopy AFM IR in pharmaceutical applications This Phase II research will advance ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: VELUM INC Topic: NIA
There is a world wide twin epidemic of obesity and TypeDiabetesT Dwith an urgent need to find effective new drug treatments for inducing weight lossStable derivatives of the endogenous glucoregulatory hormoneglucagon like peptideGLPare in clinical use for the treatment of T D but are of equally great interest as an emerging treatment of obesity and of age related neurodegenerative conditions inclu ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: MAVERIX BIOMICS, INC. Topic: NIDA
DESCRIPTION provided by applicant The broad objective of this project is to develop an integrated wet lab dry lab kit for high throughput detection of RNA modifications The final product will provide all required molecular biology reagents a set of simple and robust experimental manipulations for facile analysis of modifications and researcher friendly analytic cloud based software requi ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health